SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) will be presenting at the BIOCOM Investor Conference in
San Diego on Tuesday, October 28, 2008 at 10:30 a.m. PT. Mark G. Foletta,
Amylin's Senior Vice President of Finance and Chief Financial Officer, will
be providing a corporate overview.
The live presentation will be Web cast, and a recording will be made
available following the event. The Web cast and recording will be
accessible through Amylin's corporate Web site, located at
http://www.amylin.com. To access the live Web cast, please log on to
Amylin's site approximately fifteen minutes prior to the presentation to
register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
headquartered in San Diego, California with over 2,000 employees
nationwide. Further information on Amylin Pharmaceuticals is available at
http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com
CONTACT:
Michael York, Senior Director, Investor
Relations of Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext.
8602
|
